市場調査レポート

商品コード

1414888

インクレチン系薬剤市場：薬剤クラス別、投与経路別、流通チャネル別：世界市場機会分析と産業予測、2023-2032年

Incretin-Based Drugs Market By Drug Class, By Route of Administration, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2023-2032

出版日: 2023年11月30日 | 発行: Allied Market Research

| ページ情報: 英文 250 Pages | 納期: 2～3営業日

価格

Cloud Access (Single User License)

USD 3,570 561,775円

レポートのクラウドアクセスでご利用頂けるライセンスです。ウェブポータルで配信され、60日間レポートにアクセスできます。この期間を過ぎるとレポートへのアクセスは失効します。コンテンツのダウンロード、印刷、共有、コピー＆ペーストはできません。

PDF (Business License)

USD 5,730 901,672円

レポートPDFをご利用いただけるライセンスです。ライセンスを付与されたPCでのみレポートPDFの保存、表示、利用が可能です。PDFl内のテキスト等のコピー＆ペーストは可能です。印刷は5回可能です。追加料金を支払うことで、2～5ユーザーを収容できるようにアップグレードできます。

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

USD 9,600 1,510,656円

レポートPDFとExcel定量データをひとつの企業、及びその子会社でご利用頂けるライセンスです。ライセンスを付与されたPCでのみレポートPDFとExcelの保存、表示、利用が可能です。PDFとExcel内のテキスト等のコピー＆ペーストは可能です。PDFとExcelの印刷回数の制限はありません。印刷したレポートの利用は企業、及びその子会社内にて共有可能です。無料でレポートのアップデートがご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=157.36円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

インクレチン系薬剤市場は、医薬品セクターからの市場需要の増加により、2023年から2032年にかけて7.9%の大幅な成長率を記録する可能性が高いです。

2型糖尿病の管理においてインクレチンの作用を高めるために、DPP-4阻害薬やGLP-1類似体の使用が医薬品的アプローチとして挙げられます。DPP-4阻害薬は、DPP-4の活性を阻害することによって作用します。これらの薬剤は、循環中のグルカゴン様ペプチド（GLP-1）と胃抑制ペプチド（GIP）のレベルを上昇させる。これらのホルモンは、インスリン分泌とグルコース調節に長時間作用します。一方、合成GLP-1製剤は、DPP-4の分解に耐性のあるGLP-1トランスポーターです。合成GLP-1薬は、天然のGLP-1の作用を模倣して作用します。これらの薬剤は、インスリン分泌を増加させ、グルカゴンの分泌を抑制し、胃排出を遅らせ、食欲を減退させます。

インクレチン系薬剤市場の成長は、主に世界中で2型糖尿病患者が多いことに起因しています。2型糖尿病は、血糖値が高すぎ、体内でインスリンが十分に分泌されない状態です。世界の肥満の増加により、2型糖尿病患者数は増加傾向にあります。現在、糖尿病（2型）の治療にはインクレチン系薬剤が用いられています。これらの薬剤は、様々な方法で糖代謝を制御し、低血糖を伴い、体重に影響を与えないか、体重減少を促進しないです。そのため、この疾患の治療において大きな需要があり、インクレチン系薬剤市場の成長を後押ししています。

市場の定義と範囲
主な調査結果
- 影響要因
- 主な投資機会
ポーターのファイブフォース分析
市場力学
- 促進要因
  - 2型糖尿病の有病率の上昇
  - 市場における最近の製品承認と製品上市
  - インクレチンベースの薬物療法における最近の進歩
- 抑制要因
  - インクレチン系薬剤の高コスト
  - 薬に関する厳しい規制
- 機会
  - インクレチン系薬剤の研究開発の急増

第4章インクレチン系薬剤市場：薬剤クラス別

概要
GLP-1受容体作動薬
DPP-4阻害薬

第5章インクレチン系薬剤市場：投与経路別

概要
非経口剤
経口剤

第6章インクレチン系薬剤市場：流通経路別

概要
病院薬局
ドラッグストアおよび小売薬局
オンラインプロバイダー

第7章インクレチン系薬剤市場：地域別

概要
北米
- 米国
- カナダ
- メキシコ
欧州
- ドイツ
- フランス
- 英国
- イタリア
- スペイン
- その他
アジア太平洋
- 日本
- 中国
- インド
- オーストラリア
- 韓国
- その他
ラテンアメリカ・中東・アフリカ
- ブラジル
- サウジアラビア
- 南アフリカ
- その他

第8章競争情勢

イントロダクション
主要成功戦略
主要10社の製品マッピング
競合ダッシュボード
競合ヒートマップ
主要企業のポジショニング、2022年

第9章企業プロファイル

Eli Lilly and Company.
Merck & Co., Inc.
Takeda Pharmaceutical Company Ltd.
AstraZeneca plc
Sanofi
Sun Pharmaceutical Industries Ltd.
Lupin
Novo Nordisk A/S
Boehringer Ingelheim International GmbH
Novartis AG

図表

LIST OF TABLES

TABLE 01. GLOBAL INCRETIN-BASED DRUGS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 02. INCRETIN-BASED DRUGS MARKET FOR GLP-1 RECEPTOR AGONISTS, BY REGION, 2022-2032 ($MILLION)
TABLE 03. INCRETIN-BASED DRUGS MARKET FOR DPP-4 INHIBITORS, BY REGION, 2022-2032 ($MILLION)
TABLE 04. GLOBAL INCRETIN-BASED DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 05. INCRETIN-BASED DRUGS MARKET FOR PARENTERAL, BY REGION, 2022-2032 ($MILLION)
TABLE 06. INCRETIN-BASED DRUGS MARKET FOR ORAL, BY REGION, 2022-2032 ($MILLION)
TABLE 07. GLOBAL INCRETIN-BASED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 08. INCRETIN-BASED DRUGS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 09. INCRETIN-BASED DRUGS MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 10. INCRETIN-BASED DRUGS MARKET FOR ONLINE PROVIDERS, BY REGION, 2022-2032 ($MILLION)
TABLE 11. INCRETIN-BASED DRUGS MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 12. NORTH AMERICA INCRETIN-BASED DRUGS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 13. NORTH AMERICA INCRETIN-BASED DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 14. NORTH AMERICA INCRETIN-BASED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 15. NORTH AMERICA INCRETIN-BASED DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 16. U.S. INCRETIN-BASED DRUGS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 17. U.S. INCRETIN-BASED DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 18. U.S. INCRETIN-BASED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 19. CANADA INCRETIN-BASED DRUGS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 20. CANADA INCRETIN-BASED DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 21. CANADA INCRETIN-BASED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 22. MEXICO INCRETIN-BASED DRUGS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 23. MEXICO INCRETIN-BASED DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 24. MEXICO INCRETIN-BASED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 25. EUROPE INCRETIN-BASED DRUGS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 26. EUROPE INCRETIN-BASED DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 27. EUROPE INCRETIN-BASED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 28. EUROPE INCRETIN-BASED DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 29. GERMANY INCRETIN-BASED DRUGS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 30. GERMANY INCRETIN-BASED DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 31. GERMANY INCRETIN-BASED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 32. FRANCE INCRETIN-BASED DRUGS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 33. FRANCE INCRETIN-BASED DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 34. FRANCE INCRETIN-BASED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 35. UK INCRETIN-BASED DRUGS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 36. UK INCRETIN-BASED DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 37. UK INCRETIN-BASED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 38. ITALY INCRETIN-BASED DRUGS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 39. ITALY INCRETIN-BASED DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 40. ITALY INCRETIN-BASED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 41. SPAIN INCRETIN-BASED DRUGS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 42. SPAIN INCRETIN-BASED DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 43. SPAIN INCRETIN-BASED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 44. REST OF EUROPE INCRETIN-BASED DRUGS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 45. REST OF EUROPE INCRETIN-BASED DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 46. REST OF EUROPE INCRETIN-BASED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 47. ASIA-PACIFIC INCRETIN-BASED DRUGS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 48. ASIA-PACIFIC INCRETIN-BASED DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 49. ASIA-PACIFIC INCRETIN-BASED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 50. ASIA-PACIFIC INCRETIN-BASED DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 51. JAPAN INCRETIN-BASED DRUGS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 52. JAPAN INCRETIN-BASED DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 53. JAPAN INCRETIN-BASED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 54. CHINA INCRETIN-BASED DRUGS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 55. CHINA INCRETIN-BASED DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 56. CHINA INCRETIN-BASED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 57. INDIA INCRETIN-BASED DRUGS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 58. INDIA INCRETIN-BASED DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 59. INDIA INCRETIN-BASED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 60. AUSTRALIA INCRETIN-BASED DRUGS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 61. AUSTRALIA INCRETIN-BASED DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 62. AUSTRALIA INCRETIN-BASED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 63. SOUTH KOREA INCRETIN-BASED DRUGS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 64. SOUTH KOREA INCRETIN-BASED DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 65. SOUTH KOREA INCRETIN-BASED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 66. REST OF ASIA-PACIFIC INCRETIN-BASED DRUGS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 67. REST OF ASIA-PACIFIC INCRETIN-BASED DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 68. REST OF ASIA-PACIFIC INCRETIN-BASED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 69. LAMEA INCRETIN-BASED DRUGS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 70. LAMEA INCRETIN-BASED DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 71. LAMEA INCRETIN-BASED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 72. LAMEA INCRETIN-BASED DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 73. BRAZIL INCRETIN-BASED DRUGS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 74. BRAZIL INCRETIN-BASED DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 75. BRAZIL INCRETIN-BASED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 76. SAUDI ARABIA INCRETIN-BASED DRUGS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 77. SAUDI ARABIA INCRETIN-BASED DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 78. SAUDI ARABIA INCRETIN-BASED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 79. SOUTH AFRICA INCRETIN-BASED DRUGS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 80. SOUTH AFRICA INCRETIN-BASED DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 81. SOUTH AFRICA INCRETIN-BASED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 82. REST OF LAMEA INCRETIN-BASED DRUGS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 83. REST OF LAMEA INCRETIN-BASED DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 84. REST OF LAMEA INCRETIN-BASED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 85. ELI LILLY AND COMPANY.: KEY EXECUTIVES
TABLE 86. ELI LILLY AND COMPANY.: COMPANY SNAPSHOT
TABLE 87. ELI LILLY AND COMPANY.: PRODUCT SEGMENTS
TABLE 88. ELI LILLY AND COMPANY.: PRODUCT PORTFOLIO
TABLE 89. ELI LILLY AND COMPANY.: KEY STRATERGIES
TABLE 90. MERCK & CO., INC.: KEY EXECUTIVES
TABLE 91. MERCK & CO., INC.: COMPANY SNAPSHOT
TABLE 92. MERCK & CO., INC.: PRODUCT SEGMENTS
TABLE 93. MERCK & CO., INC.: PRODUCT PORTFOLIO
TABLE 94. TAKEDA PHARMACEUTICAL COMPANY LTD.: KEY EXECUTIVES
TABLE 95. TAKEDA PHARMACEUTICAL COMPANY LTD.: COMPANY SNAPSHOT
TABLE 96. TAKEDA PHARMACEUTICAL COMPANY LTD.: PRODUCT SEGMENTS
TABLE 97. TAKEDA PHARMACEUTICAL COMPANY LTD.: PRODUCT PORTFOLIO
TABLE 98. ASTRAZENECA PLC: KEY EXECUTIVES
TABLE 99. ASTRAZENECA PLC: COMPANY SNAPSHOT
TABLE 100. ASTRAZENECA PLC: PRODUCT SEGMENTS
TABLE 101. ASTRAZENECA PLC: PRODUCT PORTFOLIO
TABLE 102. ASTRAZENECA PLC: KEY STRATERGIES
TABLE 103. SANOFI: KEY EXECUTIVES
TABLE 104. SANOFI: COMPANY SNAPSHOT
TABLE 105. SANOFI: PRODUCT SEGMENTS
TABLE 106. SANOFI: PRODUCT PORTFOLIO
TABLE 107. SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
TABLE 108. SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
TABLE 109. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
TABLE 110. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
TABLE 111. LUPIN: KEY EXECUTIVES
TABLE 112. LUPIN: COMPANY SNAPSHOT
TABLE 113. LUPIN: PRODUCT SEGMENTS
TABLE 114. LUPIN: PRODUCT PORTFOLIO
TABLE 115. NOVO NORDISK A/S: KEY EXECUTIVES
TABLE 116. NOVO NORDISK A/S: COMPANY SNAPSHOT
TABLE 117. NOVO NORDISK A/S: PRODUCT SEGMENTS
TABLE 118. NOVO NORDISK A/S: PRODUCT PORTFOLIO
TABLE 119. NOVO NORDISK A/S: KEY STRATERGIES
TABLE 120. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: KEY EXECUTIVES
TABLE 121. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT
TABLE 122. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCT SEGMENTS
TABLE 123. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCT PORTFOLIO
TABLE 124. NOVARTIS AG: KEY EXECUTIVES
TABLE 125. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 126. NOVARTIS AG: PRODUCT SEGMENTS
TABLE 127. NOVARTIS AG: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01. INCRETIN-BASED DRUGS MARKET, 2022-2032
FIGURE 02. SEGMENTATION OF INCRETIN-BASED DRUGS MARKET,2022-2032
FIGURE 03. TOP IMPACTING FACTORS IN INCRETIN-BASED DRUGS MARKET (2022 TO 2032)
FIGURE 04. TOP INVESTMENT POCKETS IN INCRETIN-BASED DRUGS MARKET (2023-2032)
FIGURE 05. LOW BARGAINING POWER OF SUPPLIERS
FIGURE 06. LOW THREAT OF NEW ENTRANTS
FIGURE 07. LOW THREAT OF SUBSTITUTES
FIGURE 08. LOW INTENSITY OF RIVALRY
FIGURE 09. LOW BARGAINING POWER OF BUYERS
FIGURE 10. GLOBAL INCRETIN-BASED DRUGS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 11. INCRETIN-BASED DRUGS MARKET, BY DRUG CLASS, 2022 AND 2032(%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF INCRETIN-BASED DRUGS MARKET FOR GLP-1 RECEPTOR AGONISTS, BY COUNTRY 2022 AND 2032(%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF INCRETIN-BASED DRUGS MARKET FOR DPP-4 INHIBITORS, BY COUNTRY 2022 AND 2032(%)
FIGURE 14. INCRETIN-BASED DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022 AND 2032(%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF INCRETIN-BASED DRUGS MARKET FOR PARENTERAL, BY COUNTRY 2022 AND 2032(%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF INCRETIN-BASED DRUGS MARKET FOR ORAL, BY COUNTRY 2022 AND 2032(%)
FIGURE 17. INCRETIN-BASED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022 AND 2032(%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF INCRETIN-BASED DRUGS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
FIGURE 19. COMPARATIVE SHARE ANALYSIS OF INCRETIN-BASED DRUGS MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
FIGURE 20. COMPARATIVE SHARE ANALYSIS OF INCRETIN-BASED DRUGS MARKET FOR ONLINE PROVIDERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 21. INCRETIN-BASED DRUGS MARKET BY REGION, 2022 AND 2032(%)
FIGURE 22. U.S. INCRETIN-BASED DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 23. CANADA INCRETIN-BASED DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 24. MEXICO INCRETIN-BASED DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 25. GERMANY INCRETIN-BASED DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 26. FRANCE INCRETIN-BASED DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 27. UK INCRETIN-BASED DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 28. ITALY INCRETIN-BASED DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 29. SPAIN INCRETIN-BASED DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 30. REST OF EUROPE INCRETIN-BASED DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 31. JAPAN INCRETIN-BASED DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 32. CHINA INCRETIN-BASED DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 33. INDIA INCRETIN-BASED DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 34. AUSTRALIA INCRETIN-BASED DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 35. SOUTH KOREA INCRETIN-BASED DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 36. REST OF ASIA-PACIFIC INCRETIN-BASED DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 37. BRAZIL INCRETIN-BASED DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 38. SAUDI ARABIA INCRETIN-BASED DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 39. SOUTH AFRICA INCRETIN-BASED DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 40. REST OF LAMEA INCRETIN-BASED DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 41. TOP WINNING STRATEGIES, BY YEAR (2020-2023)
FIGURE 42. TOP WINNING STRATEGIES, BY DEVELOPMENT (2020-2023)
FIGURE 43. TOP WINNING STRATEGIES, BY COMPANY (2020-2023)
FIGURE 44. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 45. COMPETITIVE DASHBOARD
FIGURE 46. COMPETITIVE HEATMAP: INCRETIN-BASED DRUGS MARKET
FIGURE 47. TOP PLAYER POSITIONING, 2022
FIGURE 48. ELI LILLY AND COMPANY: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 49. ELI LILLY AND COMPANY: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 50. MERCK & CO., INC.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 51. MERCK & CO., INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 52. MERCK & CO., INC.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 53. TAKEDA PHARMACEUTICAL COMPANY LTD.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 54. TAKEDA PHARMACEUTICAL COMPANY LTD.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 55. ASTRAZENECA PLC: NET SALES, 2020-2022 ($MILLION)
FIGURE 56. ASTRAZENECA PLC: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 57. SANOFI: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 58. SANOFI: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 59. SANOFI: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 60. SUN PHARMACEUTICAL INDUSTRIES LTD.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 61. SUN PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE BY REGION, 2021 (%)
FIGURE 62. LUPIN: NET SALES, 2020-2022 ($MILLION)
FIGURE 63. LUPIN: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 64. NOVO NORDISK A/S: NET SALES, 2020-2022 ($MILLION)
FIGURE 65. NOVO NORDISK A/S: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 66. NOVO NORDISK A/S: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 67. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: NET SALES, 2020-2022 ($MILLION)
FIGURE 68. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 69. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 70. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
FIGURE 71. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 72. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)

Product Code: A00535

The incretin-based drugs market is likely to experience a significant growth rate of 7.9% from 2023-2032 owing to increasing market demand from pharmaceuticals sector - Allied Market Research

To enhance the action of incretins in managing type 2 diabetes, pharmaceutical approaches include the use of DPP-4 inhibitors and GLP-1 analogues. The DPP-4 inhibitors work by blocking DPP-4 activity. These drugs increase the levels of circulating glucagon-like peptides (GLP-1) and gastric inhibitory peptide (GIP). These hormones have a longer-lasting effect on insulin secretion and glucose regulation. On the other hand, synthetic GLP-1 drugs are GLP-1 transporters that are more tolerant to DPP-4 degradation. They work by mimicking the action of natural GLP-1. These drugs increase insulin release, inhibit glucagon secretion, slow gastric emptying, and reduce appetite.

The growth of incretin-based drugs market is mainly attributed to the high prevalence of type 2 diabetes population around the globe. Type 2 diabetes is a condition in which blood sugar levels are too high and the body is not able to produce enough insulin. The number of people with type 2 diabetes is on the rise, due to the rise in obesity around the world. Diabetes mellitus (Type 2) is currently treated using incretin-based drugs. These drugs control glucose metabolism in a variety of ways, are associated with low levels of hypoglycemia, and either do not affect body weight or do not stimulate weight loss. Thus have a huge demand in the treatment of this condition, which propels the growth of the incretin-based drugs market.

In addition, incretin-based drugs have shown promising results in weight loss or weight neutrality. This makes them attractive to a wider patient base interested in obesity management. Furthermore, ongoing R&D efforts to enhance the effectiveness, safety, and delivery mechanisms of the incretin-based therapies have also contributed to market expansion. The growing knowledge of the biology behind incretin and its impact on various metabolic disorders continue to drive innovation. This is anticipated to drive the market for incretin-based drugs in coming years.

However, the high cost of the treatment and regulatory challenges may hamper market growth to some extent. Incretin based drugs are usually more expensive than traditional diabetes drugs. Cost becomes a major issue, especially in areas where healthcare costs are high, which may limit access to these drugs. Also, the market is affected by stringent regulations and approval procedures by regulatory bodies such as the Food and Drug Administration (FDA) in the U.S. and the European Medicines Agency (EMA) in Europe. Delays or complexity in the approval of new drugs or indications may impede market growth.

The incretin-based drugs market is segmented on the basis of drug class, route of administration, distribution channel, and region. On the basis of drug class, the market is divided into GLP-1 receptor agonists and DPP-4 inhibitors. On the basis of route of administration, the market is classified into oral and parenteral. By distribution channel, the market is categorized into hospital pharmacies, drug stores & retail pharmacies, and online providers. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Major players profiled in this report are Eli Lilly and Company., Merck & Co., Inc., GlaxoSmithKline plc, Sanofi, Sun Pharmaceutical Industries Ltd., Lupin, Boehringer Ingelheim International GmbH, Novo Nordisk A/S, AstraZeneca plc and Takeda Pharmaceutical Company Ltd.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the incretin-based drugs market analysis from 2022 to 2032 to identify the prevailing incretin-based drugs market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the incretin-based drugs market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global incretin-based drugs market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

Quarterly Update and* (only available with a corporate license, on listed price)
5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
Free Upcoming Version on the Purchase of Five and Enterprise User License.
16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
Free data Pack on the Five and Enterprise User License. (Excel version of the report)
Free Updated report if the report is 6-12 months old or older.
24-hour priority response*
Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

Additional company profiles with specific to client's interest
Additional country or region analysis- market size and forecast
Average Selling Price Analysis / Price Point Analysis
Brands Share Analysis
Criss-cross segment analysis- market size and forecast
Expanded list for Company Profiles
Historic market data
Import Export Analysis/Data
Key player details (including location, contact details, supplier/vendor network etc. in excel format)
List of customers/consumers/raw material suppliers- value chain analysis
Market share analysis of players at global/region/country level
Per Capita Consumption Trends
Product Consumption Analysis
Reimbursement Scenario
SWOT Analysis
Volume Market Size and Forecast

Key Market Segments

By Drug Class

GLP-1 receptor agonists
DPP-4 inhibitors

By Route of Administration

Oral
Parenteral

By Distribution Channel

Hospital Pharmacies
Drug Stores and Retail Pharmacies
Online Providers

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA

Key Market Players:

Eli Lilly and Company.
Takeda Pharmaceutical Company Ltd.
Lupin
Novartis AG
Merck & Co., Inc.
Sun Pharmaceutical Industries Ltd.
Boehringer Ingelheim International GmbH
Sanofi
Novo Nordisk A/S
AstraZeneca plc

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
3.3. Porter's five forces analysis
- 3.3.1. Low bargaining power of suppliers
- 3.3.2. Low threat of new entrants
- 3.3.3. Low threat of substitutes
- 3.3.4. Low intensity of rivalry
- 3.3.5. Low bargaining power of buyers
3.4. Market dynamics
- 3.4.1. Drivers
  - 3.4.1.1. Rising prevalence of type-2 diabetes
  - 3.4.1.2. Recent product approvals and product launches in the market
  - 3.4.1.3. Recent advancement in Incretin-Based Pharmacotherapies
- 3.4.2. Restraints
  - 3.4.2.1. High cost of incretin-based drugs
  - 3.4.2.2. Stringent regulations related to medications
- 3.4.3. Opportunities
  - 3.4.3.1. Surge in research and development in incretin-based drugs

CHAPTER 4: INCRETIN-BASED DRUGS MARKET, BY DRUG CLASS

4.1. Overview
- 4.1.1. Market size and forecast
4.2. GLP-1 receptor agonists
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
4.3. DPP-4 inhibitors
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country

CHAPTER 5: INCRETIN-BASED DRUGS MARKET, BY ROUTE OF ADMINISTRATION

5.1. Overview
- 5.1.1. Market size and forecast
5.2. Parenteral
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
5.3. Oral
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country

CHAPTER 6: INCRETIN-BASED DRUGS MARKET, BY DISTRIBUTION CHANNEL

6.1. Overview
- 6.1.1. Market size and forecast
6.2. Hospital Pharmacies
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
6.3. Drug Stores and Retail Pharmacies
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
6.4. Online Providers
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by region
- 6.4.3. Market share analysis by country

CHAPTER 7: INCRETIN-BASED DRUGS MARKET, BY REGION

7.1. Overview
- 7.1.1. Market size and forecast By Region
7.2. North America
- 7.2.1. Key market trends, growth factors and opportunities
- 7.2.2. Market size and forecast, by Drug Class
- 7.2.3. Market size and forecast, by Route of Administration
- 7.2.4. Market size and forecast, by Distribution Channel
- 7.2.5. Market size and forecast, by country
  - 7.2.5.1. U.S.
  - 7.2.5.1.1. Market size and forecast, by Drug Class
  - 7.2.5.1.2. Market size and forecast, by Route of Administration
  - 7.2.5.1.3. Market size and forecast, by Distribution Channel
  - 7.2.5.2. Canada
  - 7.2.5.2.1. Market size and forecast, by Drug Class
  - 7.2.5.2.2. Market size and forecast, by Route of Administration
  - 7.2.5.2.3. Market size and forecast, by Distribution Channel
  - 7.2.5.3. Mexico
  - 7.2.5.3.1. Market size and forecast, by Drug Class
  - 7.2.5.3.2. Market size and forecast, by Route of Administration
  - 7.2.5.3.3. Market size and forecast, by Distribution Channel
7.3. Europe
- 7.3.1. Key market trends, growth factors and opportunities
- 7.3.2. Market size and forecast, by Drug Class
- 7.3.3. Market size and forecast, by Route of Administration
- 7.3.4. Market size and forecast, by Distribution Channel
- 7.3.5. Market size and forecast, by country
  - 7.3.5.1. Germany
  - 7.3.5.1.1. Market size and forecast, by Drug Class
  - 7.3.5.1.2. Market size and forecast, by Route of Administration
  - 7.3.5.1.3. Market size and forecast, by Distribution Channel
  - 7.3.5.2. France
  - 7.3.5.2.1. Market size and forecast, by Drug Class
  - 7.3.5.2.2. Market size and forecast, by Route of Administration
  - 7.3.5.2.3. Market size and forecast, by Distribution Channel
  - 7.3.5.3. UK
  - 7.3.5.3.1. Market size and forecast, by Drug Class
  - 7.3.5.3.2. Market size and forecast, by Route of Administration
  - 7.3.5.3.3. Market size and forecast, by Distribution Channel
  - 7.3.5.4. Italy
  - 7.3.5.4.1. Market size and forecast, by Drug Class
  - 7.3.5.4.2. Market size and forecast, by Route of Administration
  - 7.3.5.4.3. Market size and forecast, by Distribution Channel
  - 7.3.5.5. Spain
  - 7.3.5.5.1. Market size and forecast, by Drug Class
  - 7.3.5.5.2. Market size and forecast, by Route of Administration
  - 7.3.5.5.3. Market size and forecast, by Distribution Channel
  - 7.3.5.6. Rest of Europe
  - 7.3.5.6.1. Market size and forecast, by Drug Class
  - 7.3.5.6.2. Market size and forecast, by Route of Administration
  - 7.3.5.6.3. Market size and forecast, by Distribution Channel
7.4. Asia-Pacific
- 7.4.1. Key market trends, growth factors and opportunities
- 7.4.2. Market size and forecast, by Drug Class
- 7.4.3. Market size and forecast, by Route of Administration
- 7.4.4. Market size and forecast, by Distribution Channel
- 7.4.5. Market size and forecast, by country
  - 7.4.5.1. Japan
  - 7.4.5.1.1. Market size and forecast, by Drug Class
  - 7.4.5.1.2. Market size and forecast, by Route of Administration
  - 7.4.5.1.3. Market size and forecast, by Distribution Channel
  - 7.4.5.2. China
  - 7.4.5.2.1. Market size and forecast, by Drug Class
  - 7.4.5.2.2. Market size and forecast, by Route of Administration
  - 7.4.5.2.3. Market size and forecast, by Distribution Channel
  - 7.4.5.3. India
  - 7.4.5.3.1. Market size and forecast, by Drug Class
  - 7.4.5.3.2. Market size and forecast, by Route of Administration
  - 7.4.5.3.3. Market size and forecast, by Distribution Channel
  - 7.4.5.4. Australia
  - 7.4.5.4.1. Market size and forecast, by Drug Class
  - 7.4.5.4.2. Market size and forecast, by Route of Administration
  - 7.4.5.4.3. Market size and forecast, by Distribution Channel
  - 7.4.5.5. South Korea
  - 7.4.5.5.1. Market size and forecast, by Drug Class
  - 7.4.5.5.2. Market size and forecast, by Route of Administration
  - 7.4.5.5.3. Market size and forecast, by Distribution Channel
  - 7.4.5.6. Rest of Asia-Pacific
  - 7.4.5.6.1. Market size and forecast, by Drug Class
  - 7.4.5.6.2. Market size and forecast, by Route of Administration
  - 7.4.5.6.3. Market size and forecast, by Distribution Channel
7.5. LAMEA
- 7.5.1. Key market trends, growth factors and opportunities
- 7.5.2. Market size and forecast, by Drug Class
- 7.5.3. Market size and forecast, by Route of Administration
- 7.5.4. Market size and forecast, by Distribution Channel
- 7.5.5. Market size and forecast, by country
  - 7.5.5.1. Brazil
  - 7.5.5.1.1. Market size and forecast, by Drug Class
  - 7.5.5.1.2. Market size and forecast, by Route of Administration
  - 7.5.5.1.3. Market size and forecast, by Distribution Channel
  - 7.5.5.2. Saudi Arabia
  - 7.5.5.2.1. Market size and forecast, by Drug Class
  - 7.5.5.2.2. Market size and forecast, by Route of Administration
  - 7.5.5.2.3. Market size and forecast, by Distribution Channel
  - 7.5.5.3. South Africa
  - 7.5.5.3.1. Market size and forecast, by Drug Class
  - 7.5.5.3.2. Market size and forecast, by Route of Administration
  - 7.5.5.3.3. Market size and forecast, by Distribution Channel
  - 7.5.5.4. Rest of LAMEA
  - 7.5.5.4.1. Market size and forecast, by Drug Class
  - 7.5.5.4.2. Market size and forecast, by Route of Administration
  - 7.5.5.4.3. Market size and forecast, by Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

8.1. Introduction
8.2. Top winning strategies
8.3. Product mapping of top 10 player
8.4. Competitive dashboard
8.5. Competitive heatmap
8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

9.1. Eli Lilly and Company.
- 9.1.1. Company overview
- 9.1.2. Key executives
- 9.1.3. Company snapshot
- 9.1.4. Operating business segments
- 9.1.5. Product portfolio
- 9.1.6. Business performance
- 9.1.7. Key strategic moves and developments
9.2. Merck & Co., Inc.
- 9.2.1. Company overview
- 9.2.2. Key executives
- 9.2.3. Company snapshot
- 9.2.4. Operating business segments
- 9.2.5. Product portfolio
- 9.2.6. Business performance
9.3. Takeda Pharmaceutical Company Ltd.
- 9.3.1. Company overview
- 9.3.2. Key executives
- 9.3.3. Company snapshot
- 9.3.4. Operating business segments
- 9.3.5. Product portfolio
- 9.3.6. Business performance
9.4. AstraZeneca plc
- 9.4.1. Company overview
- 9.4.2. Key executives
- 9.4.3. Company snapshot
- 9.4.4. Operating business segments
- 9.4.5. Product portfolio
- 9.4.6. Business performance
- 9.4.7. Key strategic moves and developments
9.5. Sanofi
- 9.5.1. Company overview
- 9.5.2. Key executives
- 9.5.3. Company snapshot
- 9.5.4. Operating business segments
- 9.5.5. Product portfolio
- 9.5.6. Business performance
9.6. Sun Pharmaceutical Industries Ltd.
- 9.6.1. Company overview
- 9.6.2. Key executives
- 9.6.3. Company snapshot
- 9.6.4. Operating business segments
- 9.6.5. Product portfolio
- 9.6.6. Business performance
9.7. Lupin
- 9.7.1. Company overview
- 9.7.2. Key executives
- 9.7.3. Company snapshot
- 9.7.4. Operating business segments
- 9.7.5. Product portfolio
- 9.7.6. Business performance
9.8. Novo Nordisk A/S
- 9.8.1. Company overview
- 9.8.2. Key executives
- 9.8.3. Company snapshot
- 9.8.4. Operating business segments
- 9.8.5. Product portfolio
- 9.8.6. Business performance
- 9.8.7. Key strategic moves and developments
9.9. Boehringer Ingelheim International GmbH
- 9.9.1. Company overview
- 9.9.2. Key executives
- 9.9.3. Company snapshot
- 9.9.4. Operating business segments
- 9.9.5. Product portfolio
- 9.9.6. Business performance
9.10. Novartis AG
- 9.10.1. Company overview
- 9.10.2. Key executives
- 9.10.3. Company snapshot
- 9.10.4. Operating business segments
- 9.10.5. Product portfolio
- 9.10.6. Business performance

インクレチン系薬剤市場：薬剤クラス別、投与経路別、流通チャネル別：世界市場機会分析と産業予測、2023-2032年

Incretin-Based Drugs Market By Drug Class, By Route of Administration, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2023-2032

目次

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場概要

第4章インクレチン系薬剤市場：薬剤クラス別

第5章インクレチン系薬剤市場：投与経路別

第6章インクレチン系薬剤市場：流通経路別

第7章インクレチン系薬剤市場：地域別

第8章競争情勢

第9章企業プロファイル

LIST OF TABLES

LIST OF FIGURES

Key Benefits For Stakeholders

Key Market Segments

By Drug Class

By Route of Administration

By Distribution Channel

By Region

Key Market Players:

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: MARKET OVERVIEW

CHAPTER 4: INCRETIN-BASED DRUGS MARKET, BY DRUG CLASS

CHAPTER 5: INCRETIN-BASED DRUGS MARKET, BY ROUTE OF ADMINISTRATION

CHAPTER 6: INCRETIN-BASED DRUGS MARKET, BY DISTRIBUTION CHANNEL

CHAPTER 7: INCRETIN-BASED DRUGS MARKET, BY REGION

CHAPTER 8: COMPETITIVE LANDSCAPE

CHAPTER 9: COMPANY PROFILES

インクレチン系薬剤市場：薬剤クラス別、投与経路別、流通チャネル別：世界市場機会分析と産業予測、2023-2032年

Incretin-Based Drugs Market By Drug Class, By Route of Administration, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2023-2032

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

第4章 インクレチン系薬剤市場：薬剤クラス別

第5章 インクレチン系薬剤市場：投与経路別

第6章 インクレチン系薬剤市場：流通経路別

第7章 インクレチン系薬剤市場：地域別

第8章 競争情勢

第9章 企業プロファイル

LIST OF TABLES

LIST OF FIGURES

Key Benefits For Stakeholders

Key Market Segments

By Drug Class

By Route of Administration

By Distribution Channel

By Region

Key Market Players:

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: MARKET OVERVIEW

CHAPTER 4: INCRETIN-BASED DRUGS MARKET, BY DRUG CLASS

CHAPTER 5: INCRETIN-BASED DRUGS MARKET, BY ROUTE OF ADMINISTRATION

CHAPTER 6: INCRETIN-BASED DRUGS MARKET, BY DISTRIBUTION CHANNEL

CHAPTER 7: INCRETIN-BASED DRUGS MARKET, BY REGION

CHAPTER 8: COMPETITIVE LANDSCAPE

CHAPTER 9: COMPANY PROFILES

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場概要

第4章インクレチン系薬剤市場：薬剤クラス別

第5章インクレチン系薬剤市場：投与経路別

第6章インクレチン系薬剤市場：流通経路別

第7章インクレチン系薬剤市場：地域別

第8章競争情勢

第9章企業プロファイル